In the Netherlands, SGLT2 inhibitors are the preferred choice of therapy in T2D patients with a very high risk for cardiovascular events due to its shown benefits in preventing cardiovascular disease (CVD) events and progression of CKD [14]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.